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undergoing 54 AlloSCTs where donors and/or recipients were
CMV seropositive. CMV seronegative donors and recipient pairs
received leukodepleted blood products only. Prophylaxis spanned
frommyeloid recovery (ANC 750/mm3) until day100. Patients
were: M:F 29:21; mean age 8 years (0.8–20 years); donor sources:
24 HLA matched related bone marrow (BM) or peripheral blood
stem cells (PBSC), 2 related cord blood (CB), 3 MUDs, and 25
unrelated CB. HLA matching for related PBSC/BM included
twenty 6/6 and four 5/6; related CB included one 6/6 and one 5/6;
unrelated adult donors included one 10/10 and two 9/10; unrelated
CBT included two 6/6, eight 5/6 and ﬁfteen 4/6. Twenty one
(39%) patients received full intensity conditioning and 33 (61%)
patients received reduced intensity conditioning. GVHD prophy-
laxis included tacrolimus/mycophenolate mofetil as we have pre-
viously described (Osunkwo/Cairo BBMT. 2004). Mean nucleated
and CD34 cell counts were 8.1  4.9  108/kg and 5.4  2.4 
106/kg, respectively, for BM/PBSC; 4.7  2.7  107/kg and 2.6 
2.0  105/kg, respectively, for CB. Despite a 39% probability of
grade II-IV acute GVHD, no patient developed systemic CMV
disease. Twenty eight percent had grade III/IV hematological
toxicity possibly secondary to Gan/Fos. Patients developed tran-
sient nephrotoxicity and electrolyte imbalances secondary to Gan/
Fos, however no patient developed permanent renal dysfunction
and all patients were on at least 2 other concomitant nephrotoxic
drugs. Probability of 1-year overall survival was 69%. Alternate day
Gan/Fos in AlloSCT recipients where recipient and/or donor is
seropositive, especially in unrelated donor recipients, appears to be
tolerable and effective in preventing CMV systemic disease. A
future randomized trial will be required to determine if this ap-
proach not only reduces systemic CMV disease but also reduces
hematological toxicity of daily ganciclovir.
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Introduction: Antifungal therapy response is typically low in
HSCT recipients with aspergillosis. We compared (1) outcomes in
POS-treated HSCT and non-HSCT recipients with aspergillosis
with those of external controls receiving other antifungal therapy; (2)
safety of POS in HSCT and non-HSCT recipients with aspergillosis.
Methods: Patients with invasive fungal infections, including HSCT
recipients, who were intolerant of or refractory to other antifungal
therapy received oral POS 800 mg/d in divided doses in a prospective,
open-label, multicenter study. An external control group mainly in-
cluded patients concurrently hospitalized at the same institutions with
similar baseline characteristics receiving other therapy (amphotericin
B [any formulation], itraconazole, and/or investigational agents when
the study was conducted [eg, voriconazole and echinocandins]) as
salvage treatment. A blinded data review committee assessed eligibil-
ity, diagnosis, and outcome of all patients. Results: One hundred
seven of 330 patients in the POS group and 86 of 279 in the control
group had aspergillosis. Overall response was 42% (45/107) in the
POS group and 26% (22/86) in the control group (P .006; OR 4.06
[95% CI 1.5–11.04]). POS was associated with signiﬁcant survival
beneﬁt vs other therapy (P  .0003). In patients with neutropenia at
baseline (500/l), POS was associated with 24% response vs 8% in
controls. Percentage of responders was lower in HSCT recipients
than in the overall populations of both groups but was greater in
POS-treated vs control HSCT recipients. Response in POS-treated
autologous HSCT recipients was higher than in controls (Table 1) .
Response in HSCT recipients by type of leukemia is shown in the
Table. Most common adverse events (AEs) related to POS were
nausea (HSCT 11%; non-HSCT 13%), vomiting (HSCT 4%; non-
HSCT 6%), and rash (HSCT 2%; non-HSCT 6%). Convulsions
(n  2) and increased hepatic enzymes (n  2) were serious AEs in
HSCT recipients considered by the investigator to be at least possibly
related to POS. POS was well tolerated. Conclusions: There was a
signiﬁcantly greater global response rate and survival advantage in
POS-treated patients with aspergillosis vs external controls receiving
other antifungal therapy. In HSCT recipients, there was a greater
response rate in the POS group vs the control group, suggesting POS
as an option for HSCT recipients with fungal infections refractory to













Any HSCT 55 21 (38.2) 38 7 (18.4)
Allogeneic 48 15 (31.3) 34 7 (20.6)




myelogenous 14 5 (36) 5 1 (20)
Acute
lymphocytic 5 1 (20) 6 3 (50)
Chronic
myelogenous 9 6 (67) 7 0 (0)
Chronic
lymphocytic 4 0 (0) 2 1 (50)
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URSODIOL PROPHYLAXIS AGAINST HEPATIC VENO-OCCLUSIVE DIS-
EASE IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Zirakzadeh, A.1, Montori, V.1, Imran, H.1, Litzow, M.1, Kumar, S.1
Mayo College of Medicine, Rochester, MN.
Hepatic veno-occlusive disease (VOD) is a well-recognized compli-
cation of hematopoietic stem cell transplantation (HSCT). Ursodiol
has been studied as a prophylactic agent against this condition with
varying success. We performed a systematic review and meta-analysis
of the existing literature to assess the effectiveness of ursodiol in
preventing VOD in patients undergoingHSCT.We conducted com-
puterized and hand searches of ursodiol, hepatic VOD, and variations
of the two terms. We then selected those randomized trials and
observational studies which compared the incidence of VOD in
HSCT patients receiving ursodiol versus control. The outcome data
from the eligible studies were pooled and summarized (Table 1). We
also preformed an a priori subgroup analysis based on study type
(observational vs randomized clinical trial), type of conditioning reg-
imen used (busulfan vs total body irradiation based), time from urso-
diol initiation to transplant, type of transplant (allogeneic vs autolo-
gous) and different diagnostic criteria for VOD (Seattle criteria vs
modiﬁed Seattle criteria. Overall, we found that ursodiol prophylaxis
decreased the risk of VOD (pooled OR 0.33, 95% CI 0.12, 0.90). All
subgroups showed beneﬁted from ursodiol use; however wide conﬁ-
dence intervals indicate imprecision in the estimate of this beneﬁt.
Also, there was no statistically signiﬁcant difference in survival when
comparing subgroups: clinical trial versus observational study, P 
.89; busulfan vs total body irradiation, P .64; Seattle versus modiﬁed
Seattle criteria, P .36.Wewere unable to perform statistical analysis
on the type of transplant (allogeneic vs autologous), and time from
ursodiol initiation to transplant. Finally, despite our a priori subgroup
analysis, unexplained differences in results (ie, heterogeneity) contin-
ued to exist between studies. These differences were only partially
explained by analysis based on diagnostic criteria. I2 (the test statistic
used to describe heterogeneity) decreased to 0% for the modiﬁed
Seattle criteria group but remained high (76%) for the Seattle criteria
group. This review supports the assertion that ursodiol decreases the
incidence of VOD in patients receiving HSCT. However, unex-
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